Immatics N.V. (IMTX) — 6-K Filings

All 6-K filings from Immatics N.V.. Browse 27 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (27)

Immatics N.V. Files 6-K Report — Apr 17, 2026 Risk: low
Immatics N.V. filed a Form 6-K on April 17, 2026, reporting information as a foreign issuer. The filing includes documents such as the 6-K form itself, Exhibit
Immatics N.V. Updates IMA203CD8 Trial Data — Dec 11, 2025 Risk: medium
On December 11, 2025, Immatics N.V. released updated Phase 1a clinical trial data for its PRAME cell therapy, IMA203CD8. The data, with a cutoff of October 27,
Immatics N.V. Completes Share Offering — Dec 8, 2025 Risk: medium
On December 8, 2025, Immatics N.V. completed a public offering of 12,500,000 ordinary shares. This offering was conducted under an underwriting agreement with J
Immatics N.V. Reports Q3 2025 Financials and Business Update — Nov 17, 2025 Risk: low
Immatics N.V. filed an interim report on November 17, 2025, detailing its financial results and business updates for the three- and nine-month periods ending Se
6-K Filing — Nov 12, 2025
Immatics Appoints Amie Krause as Chief People Officer — Oct 27, 2025 Risk: low
Immatics N.V. announced on October 27, 2025, the appointment of Amie Krause as its new Chief People Officer, effective immediately. Ms. Krause brings over 20 ye
Immatics N.V. Updates Uveal Melanoma Trial Data — Oct 20, 2025 Risk: medium
On October 20, 2025, Immatics N.V. released updated Phase 1b clinical trial data for 16 patients with metastatic uveal melanoma treated with anzu-cel PRAME cell
Immatics Appoints Venkat Ramanan as CFO — Oct 1, 2025 Risk: low
Immatics N.V. announced on October 1, 2025, the appointment of Venkat Ramanan as its new Chief Financial Officer, effective immediately. Ramanan brings over 25
Immatics N.V. Files Q2 2025 6-K Report — Aug 13, 2025 Risk: medium
Immatics N.V. filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the second quarter of 2025, detailing expenses such
Immatics N.V. Shareholders Approve 2024 Accounts at AGM — Jun 18, 2025 Risk: low
On June 18, 2025, Immatics N.V. held its Annual General Meeting of Shareholders (AGM). Shareholders approved all agenda items, including the adoption of the sta
Immatics N.V. Updates IMA203 Trial Data — Jun 2, 2025 Risk: medium
Immatics N.V. announced on June 2, 2025, updated Phase 1b clinical trial data for its IMA203 PRAME cell therapy. The data, with a cutoff of April 7, 2025, invol
Immatics N.V. Reports Q1 2025 Financials and Business Update — May 13, 2025 Risk: low
On May 13, 2025, Immatics N.V. filed a Form 6-K to report its interim results for the three-month period ended March 31, 2025. The filing includes an interim re
Immatics N.V. Reports 2024 Financials and Updates — Mar 27, 2025 Risk: low
On March 27, 2025, Immatics N.V. released its full-year 2024 financial results and provided corporate updates. The company also made an updated investor present
Immatics N.V. Updates Investor Presentation — Jan 13, 2025 Risk: low
On January 13, 2025, Immatics N.V. released an updated investor presentation. This filing is a Form 6-K, which is a report of a foreign private issuer. The pres
BMS Terminates Immatics Allogeneic Program Collaboration — Dec 13, 2024 Risk: medium
On December 12, 2024, Bristol Myers Squibb (BMS) informed Immatics N.V. that it is terminating its collaboration agreements related to allogeneic programs. This
Immatics N.V. Reports Q3 2024 Financials and Business Update — Nov 18, 2024 Risk: low
Immatics N.V. filed a Form 6-K on November 18, 2024, to report its interim financial results for the three- and nine-month periods ended September 30, 2024. The
Immatics N.V. Presents Updated Clinical Data for IMA203 — Nov 8, 2024 Risk: medium
On November 8, 2024, Immatics N.V. reported updated Phase 1b clinical data for ACTengine® IMA203, showing positive results with a data cutoff of August 23, 2024
Immatics N.V. Completes Share Offering — Oct 15, 2024 Risk: medium
On October 15, 2024, Immatics N.V. completed an offering of 16,250,000 ordinary shares. The offering was conducted through an underwriting agreement with Jeffer
Immatics N.V. Updates on IMA203 Cell Therapy for Melanoma — Oct 10, 2024 Risk: medium
On October 10, 2024, Immatics N.V. announced updated Phase 1b clinical data for its ACTengine® IMA203 TCR-T therapy targeting PRAME in melanoma patients. The co
Immatics N.V. Shares Positive Phase 1 Data for IMA401 — Sep 16, 2024 Risk: medium
On September 16, 2024, Immatics N.V. announced proof-of-concept clinical data from its Phase 1 trial for TCER® IMA401. This novel bispecific T cell engager targ
Immatics N.V. Files Q2 2024 6-K Report — Aug 13, 2024 Risk: low
Immatics N.V. filed a 6-K report for the period ending June 30, 2024. The filing includes financial data for the second quarter of 2024, detailing expenses such
Immatics N.V. Appoints Alise Reicin to Board — Jul 31, 2024 Risk: low
On July 29, 2024, Immatics N.V. appointed Alise Reicin as a temporary non-executive director to its Board of Directors. This appointment is effective immediatel
Immatics N.V. Shareholders Approve 2023 Accounts and Discharge Boards — Jun 20, 2024 Risk: low
On June 20, 2024, Immatics N.V. held its Annual General Meeting of Shareholders (AGM). Shareholders approved all agenda items, including the adoption of the sta
Immatics N.V. Schedules Annual General Meeting for June 20 — Jun 3, 2024 Risk: low
Immatics N.V. announced on June 3, 2024, that it has made available a convening notice for its annual general meeting. The meeting is scheduled to occur on June
Immatics N.V. Reports Q1 2024 Interim Results — May 14, 2024 Risk: low
Immatics N.V. filed a Form 6-K on May 14, 2024, to report its interim results for the three-month period ended March 31, 2024. The filing includes an interim re
Immatics N.V. Reports 2023 Financial Results — Mar 21, 2024 Risk: low
On March 21, 2024, Immatics N.V. announced its full-year 2023 financial results and provided corporate updates. The company filed a Form 6-K report detailing th
Immatics N.V. Completes 18.3M Share Offering on Jan 22 — Jan 22, 2024
Immatics N.V. completed an offering of 18,313,750 ordinary shares on January 22, 2024, through an underwriting agreement with Jefferies LLC, BofA Securities, In

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX